BERKELEY, Calif., Dec. 31, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced it has selected active non-infectious anterior scleritis, which is the inflammation of the sclera (the fibrous white membrane surrounding the eyeball excluding the cornea), as the third indication in XOMA’s gevokizumab proof-of-concept program. The Company is working with the National Eye Institute (“NEI”), one of the U.S. National Institutes of Health, on designing the protocol for this study.
